{"id":"NCT01776840","sponsor":"Janssen Research & Development, LLC","briefTitle":"A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma","officialTitle":"A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-05-16","primaryCompletion":"2021-06-30","completion":"2024-06-24","firstPosted":"2013-01-28","resultsPosted":"2022-07-26","lastUpdate":"2025-07-08"},"enrollment":523,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Mantle Cell Lymphoma"],"interventions":[{"type":"DRUG","name":"Bendamustine","otherNames":[]},{"type":"DRUG","name":"Rituximab","otherNames":[]},{"type":"DRUG","name":"Ibrutinib","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Treatment Arm A","type":"PLACEBO_COMPARATOR"},{"label":"Treatment Arm B","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of ibrutinib given in combination with bendamustine and rituximab in patients 65 years of age or older with newly diagnosed mantle cell lymphoma.","primaryOutcome":{"measure":"Progression-free Survival (PFS)","timeFrame":"Up to 97 months","effectByArm":[{"arm":"Placebo + Bendamustine and Rituximab (BR) (Treatment A)","deltaMin":52.9,"sd":null},{"arm":"Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)","deltaMin":80.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.011"}]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":11},"locations":{"siteCount":201,"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","Czechia","France","Germany","Greece","Hungary","Ireland","Israel","Japan","Mexico","Netherlands","Poland","Puerto Rico","Russia","Slovakia","South Korea","Spain","Sweden","Taiwan","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["35657079"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":157,"n":260},"commonTop":["Nausea","Diarrhoea","Neutropenia","Pyrexia","Cough"]}}